Kyntra Bio/$KYNB
1D1W1MYTD1Y5YMAX
About Kyntra Bio
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
- Ticker
- $KYNB
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 34
- Headquarters
- San Francisco, United States
- Website
- www.kyntrabio.com
Kyntra Bio Metrics
BasicAdvanced
$32M
0.18
$45.27
1.04
-
Price and volume
Market cap
$32M
Beta
1.04
52-week high
$12.60
52-week low
$6.32
Average daily volume
11K
Financial strength
Current ratio
2.687
Quick ratio
2.543
Interest coverage (TTM)
-5.41%
Profitability
EBITDA (TTM)
-50.035
Gross margin (TTM)
-489.06%
Net profit margin (TTM)
3,968.63%
Operating margin (TTM)
-1,088.56%
Effective tax rate (TTM)
0.00%
Revenue per employee (TTM)
$140,000
Management effectiveness
Return on assets (TTM)
-22.50%
Return on equity (TTM)
32.68%
Valuation
Price to earnings (TTM)
0.177
Price to revenue (TTM)
7.031
Price to book
-1.08
Price to tangible book (TTM)
-1.08
Price to free cash flow (TTM)
-0.853
Free cash flow yield (TTM)
-117.27%
Free cash flow per share (TTM)
-9.405
Growth
Revenue change (TTM)
-37.16%
Earnings per share change (TTM)
-8,938.52%
3-year revenue growth (CAGR)
-67.18%
10-year revenue growth (CAGR)
-29.92%
3-year earnings per share growth (CAGR)
-18.86%
10-year earnings per share growth (CAGR)
1.13%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.